Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PFAS exposure; relationship to serum lipids in children and adults, mechanism of action and potential treatment of high exposed individuals (PFAS foreverywhere)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Denmark
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Perfluoroalkyl substances (PFAS) are widely used, persist in the environment and are present in all human populations. Many hot-spot areas across Europe in which humans are exposed through contaminated water or food has raised public concern due to the possible adverse health effects of PFAS. The overarching aim of my proposal is to determine, if PFAS exposure is causally linked to increased serum cholesterol and liver enzymes and if PFAS elimination can be enhanced. Pilot findings from our first ever randomized cross-over trial suggest that administration of the bile acid sequestrant cholestyramine significantly reduces serum PFAS in 34 high exposed individuals, probably by reducing intestinal reabsorption. In work package 1 (WP1) I will explore the promising pilot findings in a rigorously conducted randomized cross-over trial. A trial administering the food supplement psyllium, which also reduces bile reabsorption will be undertaken. PFAS exposure has been associated with increased serum cholesterol and liver enzymes, which pose a major impact to human health due to the causal link to cardiovascular diseases (CVD). It remains unclear whether the associations are causal and mechanisms by which PFAS affect lipid metabolism are not established. In WP2-3 I will study the causal relationships between child and adult PFAS exposure and serum lipids and liver enzymes in high quality prospective cohorts using a novel statistical approach (target trial emulation) to establish causal effects in observational data. In WP4 the mechanisms by which PFAS affect lipid metabolism in human liver cells will be investigated (overview see figure 2). The project will break new grounds for our understanding of the mechanism of action of PFAS on lipid metabolism and the relation with serum cholesterol and liver enzymes, as well as whether PFAS elimination can be enhanced, which will guide authorities in the handling and advise of hot-spots and regulation of PFAS to reduce future CVD.

Keywords: pfas,cholestyramine,rct,hepatocytes,cholesterol,liver enzymes,lipids,cohort,children,adults
Skin micro-injector (BoldJet)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-06-01
End date: 2023-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Needle-based injections are very common in modern medicine, notably in ongoing vaccination efforts worldwide. However, needle phobia and infection risks affect patient compliance with medical treatments, while millions of used needles contaminate the environment. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. Thus, new minimal-invasive procedures are needed. Jet injectors are needle-free medical devices that pressurize thin liquid filaments to penetrate the skin. Jet injections have been effective in subcutaneous and intramuscular delivery, ex vivo, and in vivo. However, the expected needle-free revolution for medical treatments has neither been fulfilled, nor widely commercialized due to factors such as: a) Bruising, a painful consequence of delivering large volumes in a single location. b) When using wrong energy settings, or misalignment with respect to the skin, the injected liquid can perfuse other layers. c) The rejected liquid splashes back, leading to an incorrect dose delivery, risks of cross contamination of the injector parts, or splash-back on the care giver. d) Commercial jet injection methods, such as springs or compressed gas, are noisy which can distress the patient. Hence, there is a need to develop a new way to deliver smaller doses with maximum accuracy in targeting specific skin layers. Bold-Jet is aimed at revolutionizing the experience of people who receive or perform frequent injections by developing for the first time a needle-free device using microjets that is safer, minimally invasive, and eco-friendly. By avoiding the use of needles, we can increase adherence to treatments by patients with fear to sharps and expand clinical routes for existing drugs and treatment.
Next-generation intensified chemical processes integrating plasma and single-atom catalysis (PRIME LEAP)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy,Belgium,Netherlands,United Kingdom,France,Sweden,Switzerland
Call: MSCA Doctoral Networks 2024 (HORIZON-MSCA-2024-DN-01, 2024)
Start date: 2026-01-01
End date: 2029-12-31
Duration (months): 48.0
Total project cost (EUR): 2978079.12
EU funding (EUR): 2978079.12
Participants: 13
Project status: SIGNED

PRIME LEAP tackles the grand challenge of advancing sustainable, efficient, and electrified chemical processes by focusing on the conversion of methane, a primary component of natural gas and a by-product of steam cracking, into a diverse portfolio of value-added chemicals through synergic plasma and catalysis technologies. Current progress in this sector is hindered by a shortage of trained engineers and scientists capable of designing intensified chemical processes that integrate innovative approaches such as plasma chemistry and advanced catalysis. PRIME LEAP seeks to bridge this gap by fostering a new generation of experts equipped to drive these transformative advancements and address the critical needs of the chemical sector. The project integrates cutting-edge plasma technologies, single-atom catalysts, data-driven intelligent process control, and life cycle assessment to equip doctoral candidates (DCs) with deep technical knowledge and cross-disciplinary expertise in plasma physics, chemical catalysis, methane activation, and process integration and optimization, enabling them to develop and implement next-generation methane-to-chemicals technologies. Through this multidisciplinary approach, that brings together leading academic institutions, research centers, and industrial partners, PRIME LEAP aims to cultivate a cohort of skilled professionals who can develop next-generation process intensification solutions and address the challenges of resource efficiency and carbon neutrality in the chemical industry. Overall, PRIME LEAP supports the transition toward greener, more efficient chemical methods and the project aligns with the EU’s climate goals to enhance resilience and innovation in the process industry.

Keywords: plasma chemistry methane conversion single atom catalysis computational chemistry process engineering plasma technology
Effect of climate change on greenhouse gas fluxes from marine Artic regions (GreenFlux)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Denmark,Norway
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-03-01
End date: 2025-05-31
Duration (months): 27.0
Total project cost (EUR): 230774.4
EU funding (EUR): 230774.4
Participants: 2
Project status: CLOSED

Current global warming is faster in the Arctic already affecting the region profoundly. In the Arctic, key players that likely have a strong impact on global warming are permafrost and gas hydrates, because both host large amounts of carbon. Permafrost and gas hydrates also likely occur offshore as relics of the Pleistocene. Current global warming may cause melting of these marine permafrost and gas hydrates and release more greenhouse gases into the ocean or even atmosphere (climatic feedback). However, the geologic processes that govern such melting and the sensitivity to climate change are poorly constrained. Here, I propose an original combination of approaches to assess the contribution of (sub-) Arctic marine gas hydrate and permafrost systems to marine geologic greenhouse gas emissions (GreenFlux). First, I will investigate the sensitivity of these marine systems and associated fluid flow systems to climate change across the NE Greenland shelf by using seismic and acoustic data in combination with paleo-oceanographic proxies from sediment cores. Second, a detailed study of the Kattegat, offshore Denmark, provides an analogue for the spatiotemporal evolution of sub-Arctic fluid flow systems in response to climatic changes. I will compare these two regions, one Arctic and one now temperate, to evaluate how the environmental differences impact gas release and how the Arctic is likely to develop in a future warmer world. GreenFlux will break new ground in our understanding of how climate change will influence marine gas hydrates, permafrost, and associated fluid flow in Arctic regions, and generate new knowledge on how much greenhouse gas these systems contribute to natural geologic emissions. The results will therefore be of importance to a wide audience, ranging from all Earth scientists to policy makers and the general public because they contribute to improvements of climatic models that help us as society predict and deal with the effects of climate change.

Keywords: permafrost,gas hydrates,fluid flow,paleoceanography,paleoclimate,sedimetology,seismics,hydroacustics
Temporal Evolution of the Milky-way Properties from an Observational and theoretical Sinergy (TEMPOS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Spain,Mexico
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-09-01
End date: 2025-11-30
Duration (months): 27.0
Total project cost (EUR): 165312.96
EU funding (EUR): 165312.96
Participants: 3
Project status: SIGNED

Understanding how galaxies form and evolve in the Universe is a key, long-term goal of Astrophysics. In this regard, our Galaxy provides unique insights because, due to its proximity, detailed galactic properties can be resolved that can unravel its formation history. For this reason, the international community and in particular European countries have made large investments in observational resources to perform Galactic research during this and the following decades (for example the Gaia mission and a number of ambitious spectroscopic surveys like WEAVE and 4MOST, among others). The extraordinary wealth of data is facilitating an unprecedented leap forward to uncover the origin and evolution of our Galaxy, with important implications for deciphering the physical processes governing galaxy evolution in general. In the last decade, there has been important progress in the understanding of the chemodynamic and accretion history of the Milky Way, in which the RR has played a visible role. There is, however, an important caveat in observational analysis: the lack of a methodology to derive precise stellar ages for large, unbiased samples of stars. Without the temporal dimension it is difficult to interpret observed Galactic stellar properties in terms of the processes that led to the current configuration of the Galaxy. This proposal aims to develop and exploit a novel methodology to derive precise age distributions for Milky-Way (MW) stellar populations. These age distributions will be combined with the chemo-dynamical information provided by the huge spectroscopic datasets and analyzed using chemical evolution models. Altogether, this information will provide key strong constraints to evaluate theoretical models of galaxy formation and evolution, thus approaching the study of our Galaxy through a comprehensive observational and theoretical approach.

Keywords: milky way,galactic archaeology,galaxy formation and evolution models,cosmological simulations,near field cosmology,stellar evolution,stellar populations,stellar spectroscopy,gaia
Concerted European action on Sustainable Applications of REFractories (CESAREF)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: France,Belgium,Austria,Germany,Norway,Netherlands,Canada,Sweden,Hong Kong,Korea, Republic of
Call: MSCA Doctoral Networks 2021 (HORIZON-MSCA-2021-DN-01, 2021)
Start date: 2022-10-01
End date: 2026-09-30
Duration (months): 48.0
Total project cost (EUR): 4991751.77
EU funding (EUR): 4103866.8
Participants: 25
Project status: SIGNED

Refractory materials are key enablers for high temperature industries such as Iron & Steelmaking (I&S). Refractories are sophisticated materials designed and optimized to sustain severe operation conditions inducing complex combinations of thermo-mechano-chemical damage mechanisms. Nevertheless, refractory material consumption has been reduced over the last 50 years from more than 35 kg of refractories per ton of steel to about 10 kg/t in the European steel industry, while keeping safety of the utmost importance. The movement of the I&S industry towards Net-Zero emissions and digitalized processes through disruptive, breakthrough technologies will be achieved through the use of Hydrogen. The biggest challenge for the refractory industry is to continue to meet the performance expectations while, at the same time, moving to a more sustainable production direction. The complexity and urgency of these technology changes, highlighted by the European Green Deal, requires a Concerted European Action on Sustainable Applications of REFractories (CESAREF). A consorted and coordinated European network with steel, refractory, raw material producers and key academic poles will tackle the following key topics: • Efficient use of raw materials and recycling, • Microstructure design for increased sustainability, • Anticipation of hydrogen steelmaking, • Energy efficiency and durability. While creating new developments in the I&S and refractory industries, the network will train highly skilled doctoral candidates capable of communicating and disseminating their acquired knowledge. CESAREF will create a core team across the European refractory value chain, accelerating the drive towards the European refractory industries push towards sustainable materials and processes, as well as Net-Zero emission Steel production. This will help to create and secure sustainable employment in the European refractory and I&S industries.

Keywords: refractory materials,green steel h2,raw minerals,microstructure design,life cycle assessment,energy efficiency,thermo mechanical characterization and modelling,synchrotron,multi scale approach
Dielectric Electro-Active-Polymer-driven Elastocaloric machines for a new generation of cooling systems (DEAcool)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Products and Processes Engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2025-11-01
End date: 2030-10-31
Duration (months): 60.0
Total project cost (EUR): 1499500.0
EU funding (EUR): 1499500.0
Participants: 1
Project status: SIGNED

While the global demand for cooling is rising exponentially with growing data center capacities and space cooling demands in highly populated regions (China, India, Indonesia), there is no alternative to inefficient and environmentally harmful vapor-compression systems. The search for more efficient and sustainable cooling solutions has drawn attention to novel solid-state cooling technologies like magneto-, elasto-, or electrocalorics. Specifically, elastocalorics (EC) research is showing promising results with the development of new highly-efficient materials (material COPs over 30) and several functional system devices pushing achievable cooling powers, temperature spans and system efficiencies (COP: coefficient of performance). To drive EC cooling and heating systems, either hydraulic actuators or electrical motors are used, depending on the scale and target application. To reach maximum efficiency on system level, electrical drives show most promise, yet all available drive technologies today present a bottleneck regarding the cooling systems’ construction space and weight. For future mobile cooling applications like transportation of foods and medical products, size and weight critical applications like e-mobility and aerospace or visionary cooling (or heating) textiles and wearables, alternative drives for EC systems are needed. With this project, we will for the first time use electro-active-polymer (EAP) actuator technology in EC systems and lay a foundation for future lightweight and highly integrable efficient cooling solutions. To achieve this goal, we will 1) create base knowledge on the interaction between EAPs and EC materials, 2) develop new EC cooling system concepts using EAP actuators and 3) realize several proof-of-concept demonstrators for validation in a) applications demanding compact/lightweight cooling (medical, automotive/aerospace) and b) textile integrated systems. This project will push the frontiers of sustainable and efficient cooling.

Keywords: solid state cooling elastocaloric electro active polymer dielectric elastomer actuator
OPToligo: Optimisation and scale-up of Nanostar Sieving Technology for liquid-phase synthesis of oligonucleotide therapeutics (OPToligo)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

The synthesis of oligonucleotide (oligo) therapeutics presents significant challenges in terms of scalability, cost, and sustainability. Existing methods, such as Solid Phase Oligo Synthesis (SPOS), suffer from low batch sizes, high production costs, environmental concerns, and limited scalability. Consequently, addressing medical conditions affecting large patient populations with oligo therapies remains a formidable task due to our inability to synthesise large batches of pharmaceutical-grade oligos. Exactmer introduces a groundbreaking solution to this problem through Nanostar Sieving technology. This innovative platform enables large-scale, cost-effective production of precise polymers entirely in solution, overcoming the limitations of traditional solid-phase synthesis methods. By utilizing multi-branched Nanostar hubs and proprietary membranes entirely in the liquid phase, Exactmer ensures continuous purification of growing polymers, resulting in large batch production of oligo sequences. The Nanostar Sieving technology offers unparalleled value to companies in the pharmaceutical industry. It enables the production of large batches of oligos (>50 kg; >5 mol), significantly reducing manufacturing costs by up to 35% compared to traditional methods. Moreover, Exactmer's solution minimizes environmental impact by integrating a membrane-based solvent-recycling loop, aiming to reduce solvent consumption by up to 60%. Under OPToligo, we aim to achieve these goals, improving our nanostar synthesis process for large-batch oligo production, developing membrane innovation, and lower manufacturing costs. Exactmer's Nanostar Sieving technology represents a transformative advancement in oligo synthesis, providing cheaper and more sustainable manufacturing solutions for pharmaceutical companies worldwide.

Keywords: oligonucleotide therapeutics manufacturing technology production technology,process engineering solvent recycling advanced therapeutics rna medicines
A First-in-Class Therapeutic to Overcome Immunotherapy Limitation and Improve Cancer Survival (ICI-SURVIVE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 30.0
Total project cost (EUR): 10000000.0
EU funding (EUR): 10000000.0
Participants: 1
Project status: CLOSED

58% of cancer patients receiving immune check point inhibitors (ICIs) develop gastrointestinal toxicities and cause of death is most often ruptures leading to sepsis, sepsis with multi drug resistant (MDR) bacteria is >5x more common in cancer patients. This application covers the clinical PoC for a new first-line-treatment in patients with ICI-induced colitis in a multicenter first-in-human phase 1/2a with trial healthy subjects and cancer patients on ICIs suffering from ICI-induced colitis stage 1 and 2. The main hypothesis, and driver of value, is to allow the immune system to be aggressive fighting the cancer, as induced by the ICIs - but leaving the gut alone using local acting anti-inflammatory treatment, as opposed to systemic as are used today. Systemic anti-inflammatory treatments used today, steroids and biologics, come with a number of drawbacks such as their adverse event profiles and counteracting the ICIs-effect on the cancer. The ultimate goal is to facilitate a larger portion of patients on ICI treatment to be able to complete the lifesaving treatment. The indication, non-clinical data package, proposed trial and developments are supported by FDA, as agreed from a preIND meeting, for ILP100-Oral to be evaluated as a first-line-treatment in ICI-induced colitis. We have already have interest from at least one investor in the form of medium size European pharma company to co-invest EUR 10 million alongside the EIC Fund for this project, but not alone. The Principle Investigator is global leader in ICI-induced colitis is and active at MD Andersson Cancer Center and involved with both Ilya Pharma and the anticipated co-investor. The trial is planned to be conducted both in US and Europe and a successful outcome will be disruptive for cancer care, cancer patients and payers.

Keywords: immune check point inhibitor,toxicities,cancer,multi drug resistant bacteria,sepsis,ilp100,oral